logo
  

UGI Corp. Q2 Income Advances, Beats estimates

UGI Corp. (UGI) announced a profit for its second quarter that increased from last year and beat the Street estimates.

The company's bottom line totaled $496 million, or $2.30 per share. This compares with $110 million, or $0.51 per share, in last year's second quarter.

Analysts on average had expected the company to earn $1.64 per share, according to figures compiled by Thomson Reuters. Analysts' estimates typically exclude special items.

The company's revenue for the quarter fell 20.6% to $2.47 billion from $3.11 billion last year.

UGI Corp. earnings at a glance (GAAP) :

-Earnings (Q2): $496 Mln. vs. $110 Mln. last year.
-EPS (Q2): $2.30 vs. $0.51 last year.
-Revenue (Q2): $2.47 Bln vs. $3.11 Bln last year.

For comments and feedback contact: editorial@rttnews.com

In this week's video, we highlight Roche's pioneering approach for weight loss and glucose control. Meanwhile, the EMA has taken strict action on certain preterm birth drugs and Bayer has downsized its staff. In a breakthrough for cancer treatment, the FDA has approved a groundbreaking T-cell engager therapy. Amid progress, setbacks emerge as another ALS drug study has faltered, following closely on the heels of Amylyx Pharma's recent decision to withdraw its FDA-approved ALS drug, Relyvrio.

View More Videos
RELATED NEWS
Follow RTT